title: [Is it necessary to treat Helicobacter pylori infection in patients with end-stage renal failure and in renal transplant recipients?].
abstract: Uraemic patients frequently complain of gastrointestinal ailments. There are a lot of factors responsible for the occurrence of these symptoms. It is considered--among other things--that high level of urea in gastric juice and hypergastrinaemia contribute to the damage of stomach and duodenum mucosa. Does H. pylori infection also produce pathological changes within upper gastrointestinal tract in these patients? The aim of the study was to determine the prevalence of H. pylori infection and macroscopic and microscopic estimation of oesophagus, stomach and duodenum mucosa in haemodialysis patients and renal transplant recipients. A total of 39 patients were taken under investigation: 27 among them were treated with haemodialyses and 12 were after kidney transplantation. In all patients upper gastrointestinal endoscopies were performed with collection of biopsy specimens for histological analysis and a urease test. Serological examinations were carried out in order to detect anti-CagA H. pylori antibody. In summary, we found that prevalence of H. pylori infection in uremic patients on chronic haemodialysis and renal transplant recipients was significantly lower than that in patients with normal renal function. This may be a consequence of medication and/or protection by a high urea concentration. Elevated blood urea seems to correlate with a high prevalence of gastroduodenal mucosal lesions.
authors.affiliation: Klinika Nefrologii, Transplantologii i Chorób Wewnetrznych PAM w Szczecinie.
authors.forename: Maria
authors.initials: M
authors.lastname: Korzonek
authors.forename: Ludmiła
authors.initials: L
authors.lastname: Szymaniak
authors.forename: Stefania
authors.initials: S
authors.lastname: Giedrys-Kalemba
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Ciechanowski
mesh_terms: D000368:Aged; D000907:Antibodies, Bacterial / Q000302:isolation & purification; D000942:Antigens, Bacterial / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology; D004386:Duodenum / Q000382:microbiology / Q000473:pathology; D004947:Esophagus / Q000382:microbiology / Q000473:pathology; D005260:Female; D005750:Gastric Juice / Q000737:chemistry; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000453:epidemiology / Q000628:therapy; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009092:Mucous Membrane / Q000382:microbiology / Q000473:pathology; D015995:Prevalence; D006435:Renal Dialysis; D012307:Risk Factors; D013270:Stomach / Q000382:microbiology / Q000473:pathology; D041742:Upper Gastrointestinal Tract / Q000382:microbiology* / Q000473:pathology*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C080866:cagA protein, Helicobacter pylori